Literature DB >> 22198744

Overcoming the challenges of conducting translational research in cell therapy.

Sowmya Viswanathan1, Armand Keating.   

Abstract

Cell therapy holds promise in addressing a number of unmet medical needs but despite its considerable impetus, faces numerous challenges including support for translational research in this area. Here, we examine the challenges confronting cell therapy research including the limited funding available for translational research partly due to the uncompetitive nature of required validation studies in cell therapy that of necessity are not hypothesis-driven. Other issues include lack of standardization of definitions of cell products, uncertainty regarding optimum preclinical animal models, duplication of efforts to secure regulatory approval and a lack of uniformity of nomenclature for some cell products. Nonetheless, several initiatives to address all of these issues are underway.

Mesh:

Year:  2011        PMID: 22198744     DOI: 10.1007/s11684-011-0166-2

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  5 in total

1.  The price of innovation: new estimates of drug development costs.

Authors:  Joseph A DiMasi; Ronald W Hansen; Henry G Grabowski
Journal:  J Health Econ       Date:  2003-03       Impact factor: 3.883

2.  Enhancing research in regenerative medicine.

Authors:  David A Williams; Armand Keating
Journal:  Blood       Date:  2010-08-12       Impact factor: 22.113

3.  Cost of innovation in the pharmaceutical industry.

Authors:  J A DiMasi; R W Hansen; H G Grabowski; L Lasagna
Journal:  J Health Econ       Date:  1991-07       Impact factor: 3.883

4.  Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement.

Authors:  E M Horwitz; K Le Blanc; M Dominici; I Mueller; I Slaper-Cortenbach; F C Marini; R J Deans; D S Krause; A Keating
Journal:  Cytotherapy       Date:  2005       Impact factor: 5.414

5.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Authors:  M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

  5 in total
  1 in total

1.  Cornea-Derived Mesenchymal Stromal Cells Therapeutically Modulate Macrophage Immunophenotype and Angiogenic Function.

Authors:  Medi Eslani; Ilham Putra; Xiang Shen; Judy Hamouie; Asha Tadepalli; Khandaker N Anwar; John A Kink; Samaneh Ghassemi; Gaurav Agnihotri; Sofiya Reshetylo; Alireza Mashaghi; Reza Dana; Peiman Hematti; Ali R Djalilian
Journal:  Stem Cells       Date:  2018-01-27       Impact factor: 6.277

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.